202 related articles for article (PubMed ID: 21509910)
21. Low-grade dysplasia in ulcerative colitis: risk factors for developing high-grade dysplasia or colorectal cancer.
Choi CH; Ignjatovic-Wilson A; Askari A; Lee GH; Warusavitarne J; Moorghen M; Thomas-Gibson S; Saunders BP; Rutter MD; Graham TA; Hart AL
Am J Gastroenterol; 2015 Oct; 110(10):1461-71; quiz 1472. PubMed ID: 26416190
[TBL] [Abstract][Full Text] [Related]
22. A study of indefinite for dysplasia in Barrett's oesophagus: reproducibility of diagnosis, clinical outcomes and predicting progression with AMACR (alpha-methylacyl-CoA-racemase).
Sonwalkar SA; Rotimi O; Scott N; Verghese E; Dixon M; Axon AT; Everett SM
Histopathology; 2010 Jun; 56(7):900-7. PubMed ID: 20636793
[TBL] [Abstract][Full Text] [Related]
23. Progression of low-grade dysplasia in ulcerative colitis: effect of colonic location.
Goldstone R; Itzkowitz S; Harpaz N; Ullman T
Gastrointest Endosc; 2011 Nov; 74(5):1087-93. PubMed ID: 21907984
[TBL] [Abstract][Full Text] [Related]
24. Value of cyclin A immunohistochemistry for cancer risk stratification in Barrett esophagus surveillance: A multicenter case-control study.
van Olphen SH; Ten Kate FJC; Doukas M; Kastelein F; Steyerberg EW; Stoop HA; Spaander MC; Looijenga LHJ; Bruno MJ; Biermann K;
Medicine (Baltimore); 2016 Nov; 95(47):e5402. PubMed ID: 27893678
[TBL] [Abstract][Full Text] [Related]
25. Inactivation of JNK2 as carcinogenic factor in colitis-associated and sporadic colorectal carcinogenesis.
Lessel W; Silver A; Jechorek D; Guenther T; Roehl FW; Kalinski T; Roessner A; Poehlmann-Nitsche A
Carcinogenesis; 2017 May; 38(5):559-569. PubMed ID: 28383667
[TBL] [Abstract][Full Text] [Related]
26. Aberrant p53 expression is associated with neoplastic progression in Barrett oesophagus diagnosed as indefinite for dysplasia.
Chen X; Liu BL; Harpaz N; Zhu H; Polydorides AD; Liu Q
Histopathology; 2023 Feb; 82(3):454-465. PubMed ID: 36251540
[TBL] [Abstract][Full Text] [Related]
27. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
[TBL] [Abstract][Full Text] [Related]
28. Usefulness of analysis of p53 alteration and observation of surface microstructure for diagnosis of ulcerative colitis-associated colorectal neoplasia.
Fujii S; Fujimori T; Chiba T
J Exp Clin Cancer Res; 2003 Mar; 22(1):107-15. PubMed ID: 12725330
[TBL] [Abstract][Full Text] [Related]
29. Dysplasia as a predictive marker for invasive carcinoma in Barrett esophagus: a follow-up study based on 138 cases from a diagnostic variability study.
Montgomery E; Goldblum JR; Greenson JK; Haber MM; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Zahurak ML; Hart J
Hum Pathol; 2001 Apr; 32(4):379-88. PubMed ID: 11331954
[TBL] [Abstract][Full Text] [Related]
30. Clinical significance of serum p53 antibodies in patients with ulcerative colitis and its carcinogenesis.
Yoshizawa S; Matsuoka K; Inoue N; Takaishi H; Ogata H; Iwao Y; Mukai M; Fujita T; Kawakami Y; Hibi T
Inflamm Bowel Dis; 2007 Jul; 13(7):865-73. PubMed ID: 17285596
[TBL] [Abstract][Full Text] [Related]
31. Goblet cell status in idiopathic ulcerative colitis--implication in surveillance program.
Vaiphei K; Saha M; Sharma BC; Bhasin DK; Singh K
Indian J Pathol Microbiol; 2004 Jan; 47(1):16-21. PubMed ID: 15471116
[TBL] [Abstract][Full Text] [Related]
32. Comparative analysis of copy number variations in ulcerative colitis associated and sporadic colorectal neoplasia.
Shivakumar BM; Chakrabarty S; Rotti H; Seenappa V; Rao L; Geetha V; Tantry BV; Kini H; Dharamsi R; Pai CG; Satyamoorthy K
BMC Cancer; 2016 Apr; 16():271. PubMed ID: 27080994
[TBL] [Abstract][Full Text] [Related]
33. IMP3 Immunoreactivity is More Sensitive Than AMACR in Detecting Dysplastic Epithelium and Early Adenocarcinoma in Barrett Esophagus.
Gadara MR; Gonzalez M; Cartun RW; Ligato S
Appl Immunohistochem Mol Morphol; 2017 Jul; 25(6):386-391. PubMed ID: 26766126
[TBL] [Abstract][Full Text] [Related]
34. Combined alpha-methylacyl coenzyme A racemase/p53 analysis to identify dysplasia in inflammatory bowel disease.
Marx A; Wandrey T; Simon P; Wewer A; Grob T; Reichelt U; Minner S; Simon R; Spehlmann M; Tigges W; Soehendra N; Seitz U; Seewald S; Izbicki JR; Yekebas E; Kaifi JT; Mirlacher M; Terracciano L; Fleischmann A; Raedler A; Sauter G
Hum Pathol; 2009 Feb; 40(2):166-73. PubMed ID: 18835622
[TBL] [Abstract][Full Text] [Related]
35. Outcome of "indefinite for dysplasia" in inflammatory bowel disease: correlation with DNA flow cytometry and other risk factors of colorectal cancer.
Choi WT; Rabinovitch PS; Wang D; Westerhoff M
Hum Pathol; 2015 Jul; 46(7):939-47. PubMed ID: 25962315
[TBL] [Abstract][Full Text] [Related]
36. Are dysplasia and colorectal cancer endoscopically visible in patients with ulcerative colitis?
Rubin DT; Rothe JA; Hetzel JT; Cohen RD; Hanauer SB
Gastrointest Endosc; 2007 Jun; 65(7):998-1004. PubMed ID: 17451704
[TBL] [Abstract][Full Text] [Related]
37. A Biomarker Panel to Detect Synchronous Neoplasm in Non-neoplastic Surveillance Biopsies from Patients with Ulcerative Colitis.
Garrity-Park MM; Loftus EV; Bryant SC; Smyrk TC
Inflamm Bowel Dis; 2016 Jul; 22(7):1568-74. PubMed ID: 27135485
[TBL] [Abstract][Full Text] [Related]
38. p53 protein overexpression in low grade dysplasia (LGD) in Barrett's esophagus: immunohistochemical marker predictive of progression.
Weston AP; Banerjee SK; Sharma P; Tran TM; Richards R; Cherian R
Am J Gastroenterol; 2001 May; 96(5):1355-62. PubMed ID: 11374668
[TBL] [Abstract][Full Text] [Related]
39. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis.
Ullman T; Croog V; Harpaz N; Sachar D; Itzkowitz S
Gastroenterology; 2003 Nov; 125(5):1311-9. PubMed ID: 14598247
[TBL] [Abstract][Full Text] [Related]
40. Dysplasia in ulcerative colitis--clinical consequences?
Sjöqvist U
Langenbecks Arch Surg; 2004 Oct; 389(5):354-60. PubMed ID: 15605166
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
